Ignyta 10-K 28 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 25, 2014	Jun. 28, 2013
Entity Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'RXDX	'	'
Entity Registrant Name	'IGNYTA, INC.	'	'
Entity Central Index Key	'0001557421	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	13,534,876	'
Entity Public Float	'	'	$0

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$51,803,716	$5,032,307
Prepaid expenses and other current assets	671,373	95,164
Total current assets	52,475,089	5,127,471
Fixed Assets-Net	830,706	294,477
Other Assets	13,045	21,697
Assets, Total	53,318,840	5,443,645
Current Liabilities	'	'
Accounts payable	811,600	291,955
Accrued expenses and other liabilities	590,235	54,092
Notes payable, current portion	'	112,129
Warrant liability	129,400	24,500
Total current liabilities	1,531,235	482,676
Notes payable, net of current portion	8,950,000	367,701
Other liabilities	1,050,000	32,500
Total liabilities	11,531,235	882,877
Commitments and Contingencies (Note 10)	'	'
Stockholders' Equity	'	'
Common Stock, value	139	65
Additional paid-in capital	57,360,406	5,919,733
Deficit accumulated during the development stage	-15,572,940	-1,359,297
Total stockholders' equity	41,787,605	4,560,768
Liabilities and Equity, Total	53,318,840	5,443,645
Series A Convertible Preferred Stock	'	'
Stockholders' Equity	'	'
Preferred Stock, value	'	84
Series B Convertible Preferred Stock	'	'
Stockholders' Equity	'	'
Preferred Stock, value	'	$183

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	0
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	13,934,876	653,334
Common Stock, shares outstanding	13,934,876	653,334
Series A Convertible Preferred Stock	'	'
Preferred Stock, par value	$0	$0.00
Preferred Stock, shares authorized	0	2,500,000
Preferred Stock, shares issued	0	833,334
Preferred Stock, shares outstanding	0	833,334
Preferred Stock, liquidation preference	$0	$0
Series B Convertible Preferred Stock	'	'
Preferred Stock, par value	$0	$0.00
Preferred Stock, shares authorized	0	7,000,000
Preferred Stock, shares issued	0	1,835,000
Preferred Stock, shares outstanding	0	1,835,000
Preferred Stock, liquidation preference	$0	$0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		28 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue	'	'	'
Expenses	'	'	'
Research and development	10,170,866	708,043	10,918,779
General and administrative	3,730,941	547,882	4,318,398
Loss from Operations	-13,901,807	-1,255,925	-15,237,177
Other Expense	'	'	'
Other income (expense)	-105,952	'	-105,952
Interest expense	-203,789	-22,619	-226,408
Total Other Expense	-309,741	-22,619	-332,360
Loss Before Income Taxes	-14,211,548	-1,278,544	-15,569,537
Income tax provision	2,095	1,308	3,403
Net Loss	($14,213,643)	($1,279,852)	($15,572,940)
Basic and diluted loss per share	($3.83)	($2)	'
Weighted average shares outstanding	3,711,885	640,364	'

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)

Total

Series A Preferred Stock

Series B Preferred Stock [Member]

Series A Convertible Preferred Stock

Series A Convertible Preferred Stock

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Common Stock

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Deficit Accumulated During the Development Stage

Series A Preferred Stock

Series B Preferred Stock [Member]

Series A Preferred Stock

Series B Preferred Stock [Member]

Balance at Dec. 31, 2010

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of Restricted Stock

$2,000

'

'

'

'

'

'

$66

$1,934

'

'

'

Issuance of Restricted Stock (in shares)

666,668

'

'

'

'

'

'

666,668

'

'

'

'

Issuance of Stock net in offering costs

'

220,778

'

'

42

'

'

'

'

220,736

'

'

Issuance of Stock net in offering costs (in shares)

'

'

'

'

416,667

'

'

'

'

'

'

'

Stock-based compensation expense

781

'

'

'

'

'

'

'

781

'

'

'

Net loss

-79,445

'

'

'

'

'

'

'

'

'

'

-79,445

Balance at Dec. 31, 2011

144,114

'

'

42

'

'

'

66

223,451

'

'

-79,445

Balance (in shares) at Dec. 31, 2011

'

'

'

416,667

'

'

'

666,668

'

'

'

'

Repurchase of Common Stock

-40

'

'

'

'

'

'

-1

-39

'

'

'

Repurchase of Common Stock (in shares)

13,334

'

'

'

'

'

'

-13,334

'

'

'

'

Issuance of Stock net in offering costs

'

249,142

5,424,031

'

42

'

183

'

'

249,100

5,423,848

'

Issuance of Stock net in offering costs (in shares)

'

'

'

'

416,667

'

1,835,000

'

'

'

'

'

Stock-based compensation expense

23,373

'

'

'

'

'

'

'

23,373

'

'

'

Net loss

-1,279,852

'

'

'

'

'

'

'

'

'

'

-1,279,852

Balance at Dec. 31, 2012

4,560,768

'

'

84

'

183

'

65

5,919,733

'

'

-1,359,297

Balance (in shares) at Dec. 31, 2012

'

'

'

833,334

'

1,835,000

'

653,334

'

'

'

'

Issuance of Common Stock due to stock options exercised

3,000

'

'

'

'

'

'

1

2,999

'

'

'

Issuance of Common Stock due to stock options exercised (in shares)

12,290

'

'

'

'

'

'

12,290

'

'

'

'

Issuance of Restricted Stock due to Actagene merger

5,700

'

'

'

'

'

'

158

5,542

'

'

'

Issuance of Restricted Stock due to Actagene merger (in shares)

'

'

'

'

'

'

'

1,583,336

'

'

'

'

Conversion of Common Stock due to merger

'

'

'

-84

'

-183

'

-175

442

'

'

'

Conversion of Common Stock due to merger ( in share)

'

'

'

-833,334

'

-1,835,000

'

2,675,678

'

'

'

'

Issuance of Stock net in offering costs

51,013,651

'

'

'

'

'

'

90

51,013,651

'

'

'

Issuance of Stock net in offering costs (in shares)

'

'

'

'

'

'

'

9,010,238

'

'

'

'

Stock-based compensation expense

370,439

'

'

'

'

'

'

'

370,439

'

'

'

Issuance of Warrant

47,600

'

'

'

'

'

'

'

47,600

'

'

'

Net loss

-14,213,643

'

'

'

'

'

'

'

'

'

'

-14,213,643

Balance at Dec. 31, 2013

$41,787,605

'

'

'

'

'

'

$139

$57,360,406

'

'

($15,572,940)

Balance (in shares) at Dec. 31, 2013

'

'

'

'

'

'

'

13,934,876

'

'

'

'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2013
	Series A Preferred Stock	Series A Preferred Stock	Series B Preferred Stock [Member]	Common Stock
Issuance of stock, offering cost	$858	$29,221	$80,969	$3,047,687

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		28 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash Flows From Operating Activities	'	'	'
Net loss	($14,213,643)	($1,279,852)	($15,572,940)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	112,380	13,892	126,272
Loss on sale of assets	29,351	'	29,351
Stock-based compensation	370,439	23,373	394,593
Non-cash interest expense	105,012	5,744	110,756
Change in fair value of warrant liabilities	76,600	0	76,600
Warrant issued for license agreement	47,600	'	47,600
Amortization of debt discount	48,470	4,330	52,800
Increase (decrease) in cash resulting from changes in:	'	'	'
Prepaid expenses and other current assets	-672,569	-117,422	-795,174
Accounts payable	519,645	272,732	811,600
Accrued expenses and other liabilities	503,643	86,592	590,235
Net cash used in operating activities	-13,073,072	-990,611	-14,128,307
Cash Flows From Investing Activities	'	'	'
Purchases of fixed assets	-687,960	-306,096	-996,329
Proceeds received from sale of assets	10,000	'	10,000
Net cash used in investing activities	-677,960	-306,096	-986,329
Cash Flows From Financing Activities	'	'	'
Net proceeds from issuance of Common Stock	51,013,741	'	51,013,741
Proceeds from issuance of notes payable	11,000,000	500,000	11,500,000
Payments on notes payable	-1,500,000	'	-1,500,000
Net proceeds from issuance of Restricted Stock	5,700	'	7,700
Net proceeds from issuance of Preferred Stock	'	5,673,173	5,893,951
Net proceeds from stock options exercised	3,000	'	3,000
Repurchase of Common Stock	'	-40	-40
Net cash provided by financing activities	60,522,441	6,173,133	66,918,352
Net Change in Cash and Cash Equivalents	46,771,409	4,876,426	51,803,716
Cash and Cash Equivalents at Beginning of Period	5,032,307	155,881	'
Cash and Cash Equivalents at End of Period	51,803,716	5,032,307	51,803,716
Supplemental Disclosures of Cash Flow Information:	'	'	'
Interest	51,122	10,335	61,457
Income taxes	2,095	1,309	3,404
Noncash Investing and Financing Activities:	'	'	'
Final loan fee issued with debt financing recorded as debt discount	1,050,000	'	1,050,000
Warrants issued with debt financing recorded as debt discount	$28,300	$24,500	$52,800

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
	1. Summary of Significant Accounting Policies		A summary of the Company’s significant accounting policies consistently applied in the preparation of the accompanying financial statements follows.
	Nature of operations		Ignyta, Inc. was founded in 2012 and is incorporated in the state of Nevada. On October 31, 2013, Ignyta Operating, Inc. (a Delaware corporation founded in 2011 and previously named Ignyta, Inc.) merged with and into IGAS Acquisition Corp., a wholly-owned subsidiary of Ignyta, Inc., which was previously named “Infinity Oil & Gas Company” (see Note 2). As used in these financial statements, unless the context indicates or otherwise requires, the “Company”, “we”, “us”, and “our” refer to Ignyta, Inc. and its consolidated subsidiary, and the term “Ignyta Operating” refers to Ignyta Operating, Inc.
			In May 2013, Ignyta Operating acquired Actagene Oncology, Inc. (“Actagene”), a San Diego based privately held biotechnology company developing precision medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. With the acquisition, Ignyta Operating changed its business strategy from a prior focus on molecular diagnostics for autoimmune disease to an integrated drug and diagnostic, or Rx/Dx, focus on drug and biomarker discovery and development for oncology (see Note 3).
			The Company is a precision medicine biotechnology company dedicated to discovering or acquiring, then developing and commercializing precisely targeted new drugs for cancer patients whose tumors harbor specific molecular alterations. The Company pursues an Rx/Dx strategy, where it aims to pair each of its innovative drugs with biomarker-based companion diagnostics, developed by the Company or by third parties with which it may partner, that are designed to identify the patients that are most likely to benefit from the use of the drugs that the Company may develop.
	Consolidation		The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). All significant intercompany balances and transactions have been eliminated in consolidation.
	Development stage		As of December 31, 2013, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure, and has not realized revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.
	Liquidity		As of December 31, 2013, the Company had an accumulated deficit of approximately $15,573,000. The Company also had negative cash flow from operations of approximately $13,073,000 during the twelve months ended December 31, 2013.
			On November 6, 2013, the Company completed a Private Investment in Public Equity (“PIPE”) financing where it issued 7,740,142 shares of its common stock to 52 accredited investors at six dollars ($6.00) per share for gross proceeds of approximately $46.4 million (see Note 6).
			On November 29, 2013, the Company completed a Subsequent Private Placement with 195 accredited investors providing for the issuance and sale to such investors of an aggregate of 1,270,096 shares of its common stock at a purchase price of six dollars ($6.00) per share for gross proceeds of approximately $7.6 million (see Note 6).
			On December 31, 2013, the Company entered into an amended and restated loan and security agreement with a financial institution with gross proceeds totaling approximately $10,000,000 (see Note 5).
			The Company will need additional capital to further fund development, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are currently focused primarily on the development of our RXDX-101, RXDX-102, Spark-1, Spark-2 and Spark-3 programs, which we believe will result in our continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of our products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to
			achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing from existing and prospective investors. We cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.
			While we expect that our existing cash and cash equivalents will enable us to fund our operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require us to delay, reduce, or eliminate some or all of our development programs. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
	Use of estimates		The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in computing the valuation allowance on deferred tax assets, the valuation of warrants, and those assumed in calculating stock-based compensation expense.
	Cash and cash equivalents		The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash equivalents primarily represent amounts invested in money market funds whose cost equals market value.
	Fixed assets		Fixed assets are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally three to five years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term.
	Impairment of long-lived assets		In accordance with authoritative guidance related to impairment or disposal of long-lived assets, management reviews the Company’s long-lived asset groups for impairment whenever events indicate that their carrying amount may not be recoverable. When management determines that one or more impairment indicators are present for an asset group, it compares the carrying amount of the asset group to net future undiscounted cash flows that the asset group is expected to generate. If the carrying amount of the asset group is greater than the net future undiscounted cash flows that the asset group is expected to generate, it compares the fair value to the book value of the asset group. If the fair value is less than the book value, it recognizes an impairment loss. The impairment loss would be the excess of the carrying amount of the asset group over its fair value. To date, the Company has not experienced any impairment losses on its long-lived assets used in operations.
	Stock-based compensation		The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation—Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
			The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
	Fair value of financial instruments		The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses, and notes payable. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of December 31, 2013 and December 31, 2012, the carrying amounts are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
	Derivative liabilities		The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future events, expected volatility, expected life, yield, and risk free interest rate.
	Income taxes		Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
	Earnings per share		Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of common shares outstanding. The Company’s basic and fully diluted EPS calculation are the same since the increased number of shares that would be included in the diluted calculation from assumed exercise of stock equivalents would be anti-dilutive to the net loss in each of the years shown in the consolidated financial statements.
	(“EPS”)
	Comprehensive income (loss)		Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended December 31, 2013 and 2012, and for the period August 29, 2011 (inception) through December 31, 2013, the comprehensive loss was equal to the net loss.
	Research and development costs		The Company is actively engaged in new product development efforts for which related costs are expensed as incurred.
	Fair value measurement		Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
			•       Level 1—Quoted prices in active markets for identical assets or liabilities.
			•       Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
			•       Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
			As of December 31, 2013, the Company’s Level 1 investments of cash and cash equivalents were comprised of cash in checking accounts.
			The Company used Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a binomial option pricing model based on various assumptions (see Note 8). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to fair value of derivative liabilities.
			At December 31, 2013, the estimated fair values of the liabilities measured on a recurring basis are as follows:
	Fair Value Measurements at December 31, 2013
	Balance at				Quoted Prices in	Significant	Significant
					Active Markets	Other	Other
	December 31, 2013				(Level 1)	Observable	Unobservable
						Inputs (Level 2)	Inputs (Level 3)
	$	129,400			—	—	$	129,400
	Fair Value Measurements at December 31, 2012
	Balance at				Quoted Prices in	Significant	Significant Other
							Unobservable
	December 31, 2012				Active Markets	Other	Inputs (Level 3)
					(Level 1)	Observable
						Inputs (Level 2)
	$	24,500			—	—	$	24,500
			The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the twelve months ended December 31, 2013:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
			Warrant Derivative
			Liability
	Beginning Balance at December 31, 2011		$	—
	Issuances			24,500
	Ending Balance at December 31, 2012		$	24,500
	Issuances			28,300
	Adjustments to estimated fair value			76,600
	Ending Balance at December 31, 2013		$	129,400

Reverse_Merger

Reverse Merger	12 Months Ended
	Dec. 31, 2013
Reverse Merger	'
	2. Reverse Merger	For purposes of the below description of the Merger, the PIPE financing and the Ignyta Plan (each as defined below), all references to “Ignyta” shall refer to Ignyta, Inc., a Nevada corporation whose name was changed from Infinity Oil & Gas Company on October 31, 2013 in connection with the closing of the Merger; and all references to “Merger Sub” shall refer to IGAS Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Ignyta.
		On October 31, 2013, Ignyta, Merger Sub, and Ignyta Operating entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). The Merger Agreement provided for the merger of Merger Sub with and into Ignyta Operating (the “Merger”), with Ignyta Operating surviving the transaction as a wholly owned subsidiary of Ignyta. The Merger closed on October 31, 2013 concurrently with the execution and delivery of the Merger Agreement.
		Also on October 31, 2013, prior to the execution and delivery of the Merger Agreement and the concurrent closing of the Merger, (i) the holders of all series of outstanding preferred stock of Ignyta Operating, consisting of Series A Preferred Stock and Series B Preferred Stock, voluntarily converted such shares into shares of Ignyta Operating’s common stock in accordance with the certificate of incorporation of Ignyta Operating and at the then-effective conversion rates therefor, which were one-to-one in all cases, and (ii) Ignyta Operating amended its certificate of incorporation to change its name to “Ignyta Operating, Inc.” and
		to effect a three-to-one reverse stock split of its capital stock, resulting in 4,916,469 outstanding shares of Ignyta Operating’s common stock, outstanding warrants to acquire up to an aggregate of 25,001 shares of Ignyta Operating’s common stock, and outstanding options granted under Ignyta Operating’s 2011 Stock Incentive Plan (as amended and restated, the “Ignyta Plan”) to purchase up to an aggregate of 358,986 shares of Ignyta Operating’s common stock.
		At the closing of the Merger and pursuant to the terms of the Merger Agreement, Ignyta issued an aggregate of 4,916,469 shares of its common stock to the former stockholders of Ignyta Operating in exchange for all of the outstanding shares of Ignyta Operating’s capital stock. That number of shares was negotiated and agreed to by Ignyta and Ignyta Operating prior to entering into the Merger Agreement. As of immediately following the closing of the Merger, Ignyta Operating became a wholly-owned subsidiary of Ignyta, and the former stockholders of Ignyta Operating collectively owned approximately 99.85% of the outstanding shares of Ignyta’s common stock. In addition, pursuant to the terms of the Merger Agreement, as of the closing of the Merger Ignyta assumed (i) the Ignyta Plan, under which an aggregate of 342,209 shares were reserved for issuance pursuant to future equity grants, (ii) the obligation to issue up to an aggregate of 358,986 shares of its common stock upon the exercise of all options granted under the Ignyta Plan that were outstanding as of immediately prior to the closing of the Merger, and (iii) the obligation to issue up to an aggregate of 25,001 shares of its common stock upon the exercise of two warrants previously issued by Ignyta Operating and outstanding as of immediately prior to the closing of the Merger.

Actagene_Merger

Actagene Merger	12 Months Ended
	Dec. 31, 2013
Actagene Merger	'
	3. Actagene Merger	In May 2013 Ignyta Operating entered into an Agreement and Plan of Reorganization with Actagene. In accordance with the agreement, Actagene was merged into Ignyta Operating and the separate corporate existence of Actagene ceased, with Ignyta Operating continuing as the surviving corporation. On May 20, 2013, the merger was effected and Ignyta Operating issued 1,583,336 shares of restricted common stock in exchange for the cancellation of all of the outstanding shares of Actagene.
		The merger was accounted for as a combination of entities under common control. The majority stockholder of Ignyta Operating was also the majority stockholder of Actagene, with approximately 60% of the voting power in each entity. Additionally, representatives of the majority stockholder controlled the day to day operations and were on the board of directors of each entity.

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2013
Fixed Assets	'
	4. Fixed Assets	Fixed assets consisted of the following:
		December 31,
		2013			2012
	Manufacturing and lab equipment	$	775,872		$	288,434
	Office furniture and equipment		59,095			6,646
	Computers		110,857			7,332
	Leasehold improvements		—			5,957
			945,824			308,369
	Less accumulated depreciation and amortization		(115,118	)		(13,892	)
		$	830,706		$	294,477
		Depreciation expense for years ended December 31, 2013 and 2012 and for the period from inception (August 29, 2011) through December 31, 2013 was $112,380, $13,892 and $126,272, respectively.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2013
Notes Payable	'
	5. Notes Payable	On December 31, 2013 the Company entered into an amended and restated loan and security agreement (the “New Loan Agreement”) with a financial institution. The New Loan Agreement replaces the prior loan and security agreement which was first entered into in June 2012 and amended in February 2013. The maximum borrowing amount under the New Loan Agreement was increased from $1,500,000 to $10,000,000. All principal and interest due on the prior Loan Agreement was paid in full and the Company was advanced the net proceeds on December 31, 2013. Payments of principal and interest are due on the New Loan Agreement on a fully amortized basis of 36 months in equal monthly installments, commencing after a twelve-month period of interest only payments, such that all amounts owed under the New Loan Agreement will mature on December 1, 2017. Upon such maturity date, the Company will also owe to the
		lender a final payment of $1,050,000, equal to 10.50% of the full principal amount under the New Loan Agreement. The final payment of $1,050,000 is presented as a debt discount on the related debt to be amortized to interest expense. Interest on the $10,000,000 note was fixed on the date of funding at 6.92%. The loan is collateralized by substantially all of the assets of the Company, other than its intellectual property.
		During 2012 Ignyta Operating entered a Loan Agreement (“the Loan Agreement”) with a financial institution with a maximum borrowing amount of $500,000. This Loan Agreement was amended on February 27, 2013 increasing the available maximum borrowing amount to $1,500,000, subject to certain milestones as defined in the Loan Agreement.
		Ignyta Operating was advanced $500,000 on June 28, 2012 under the Loan Agreement. The payments of principal and interest were due on the advance on a fully amortized basis of 36 months in equal monthly installments, commencing after a fifteen-month period of interest only payments. Interest on the $500,000 advanced in June 2012 was fixed on the date of funding at 4.77%.
		Ignyta Operating was advanced an additional $500,000 on February 27, 2013 in connection with entering into an amendment to the Loan Agreement with the lender on that date. The payments of principal and interest were due on the advance on a fully amortized basis of 30 months in equal monthly installments, commencing after a six-month period of interest only payments. Interest on the $500,000 advanced in February 2013 was fixed on the date of funding at 4.0%.
		In July 2013 Ignyta Operating was advanced the final $500,000 under the Loan Agreement, as amended. The payments of principal and interest were due on the advance on a fully amortized basis of 24 months in equal monthly installments, commencing after a two-month period of interest only payments. Interest on the $500,000 advanced in July 2013 was fixed on the date of funding at 4.04%.
		All three advances were repaid in 2013.
		As additional consideration for the cost and risk associated with the Loan Agreement, Ignyta Operating issued to the lender a warrant to purchase up to 8,334 shares of Series B Preferred Stock in June 2012, and an additional warrant to purchase up to a number of shares of Series B Preferred Stock equal to 5% of the amount loaned under the Loan Agreement on February 27, 2013 and thereafter, subject to adjustment as set forth in the warrant, including without limitation for stock combinations and splits. As a result, following the advance in July 2013, the warrant became exercisable for 16,667 shares of Ignyta Operating’s Series B Preferred Stock. The warrants issued in 2013 and 2012 were recorded at fair values of $28,300 and $24,500, respectively, and were presented as a debt discount on the related debt to be amortized to interest expense over the term of the Loan Agreement (See Note 8). Both warrants were assumed by Ignyta, Inc. in connection with the Merger (see Note 2). No new warrants were issued in conjunction with the New Loan Agreement, and as a result of the payoff of the original loan, the debt discount was written off on December 31, 2013.
		Interest expense due to amortization of the debt discount for periods ended December 31, 2013 and 2012 and for the period from inception (August 29, 2011) through December 31, 2013 was $48,470, $4,330 and $52,800, respectively.
		Future minimum principal payments on notes payable are as follows:
	Year ending December 31,
	2014	$	—
	2015		3,103,479
	2016		3,327,074
	2017		3,569,447
	Total	$	10,000,000

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity	'
	6. Stockholders’ Equity	As of December 31, 2013, the Company was authorized to issue 100,000,000 shares of common stock and 10,000,000 shares of preferred stock, with the preferred stock having the rights, preferences and privileges that our Board of Directors may determine from time to time. Each share of the Company’s common stock is entitled to one vote and all shares rank equally as to voting and other matters.
		On November 6, 2013, the Company completed a PIPE financing, providing for the issuance and sale of an aggregate of 7,740,142 shares of its common stock to 52 accredited investors at six dollars ($6.00) per share, for gross proceeds of approximately $46.4 million.
		On November 29, 2013, the Company completed a subsequent PIPE financing with 195 accredited investors, providing for the issuance and sale to such investors of an aggregate of 1,270,096 shares of its common stock at a purchase price of six dollars ($6.00) per share, for gross proceeds of approximately $7.6 million.
		On October 31, 2013, Ignyta, Inc. approved a 100-for-1 reverse stock split of its capital stock, and Ignyta Operating approved a 3-for-1 reverse stock split of its capital stock. The par value of Ignyta Inc.’s outstanding capital stock changed from $0.0001 to $0.00001 per share. The stockholders’ equity section of the accompanying financial statements and all share numbers disclosed throughout the financial statements have been retroactively adjusted to give effect to the reverse stock split.
	Series A Convertible Preferred Stock	During 2012, Ignyta Operating issued 416,667 shares of Series A Preferred Stock at $0.60 per share for proceeds consisting of $250,000 in cash.
		During 2011, Ignyta Operating issued 416,667 shares of Series A Preferred Stock at $0.60 per share for proceeds consisting of $250,000 in cash.
		On October 31, 2013, the holders of shares of Ignyta Operating’s Series A Preferred Stock elected to convert all issued and outstanding shares of such preferred stock into shares of common stock at the applicable conversion rate, which in each case was one-to-one. Ignyta Operating then effected a reverse stock split of all issued and outstanding capital stock at a ratio of three-to-one.
	Series B Convertible Preferred Stock	During 2012, Ignyta Operating issued 1,835,000 shares of Series B Preferred Stock at $3.00 per share for proceeds consisting of $5,505,000 in cash.
		On October 31, 2013, the holders of shares of Ignyta Operating’s Series B Preferred Stock elected to convert all issued and outstanding shares of such preferred stock into shares of common stock at the applicable conversion rate, which in each case was one-to-one. Ignyta Operating then effected a reverse stock split of all issued and outstanding capital stock at a ratio of three-to-one.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Stock-Based Compensation	'
	7. Stock-Based Compensation	In 2011, Ignyta Operating adopted the Ignyta Plan. The Plan provided for the issuance of incentive stock options to employees and nonstatutory stock options, restricted stock awards, stock appreciation rights and stock bonuses to directors, employees and consultants. The Ignyta Plan was assumed by Ignyta, Inc. in connection with the Merger (see Note 2). In February 2013, October 2013 and December 2013, the Plan was amended to, among other things, increase the number of shares of the Company’s common stock available for issuance thereunder from 166,666 shares to 666,666 shares, to 712,652 shares and to 2,712,652 shares, respectively.
	Stock option activity	There are a total of 2,712,652 shares of common stock reserved under the Ignyta Plan. As of December 31, 2013, 1,567,209 shares remained available for grant. The options that are granted under the Ignyta Plan are exercisable at various dates and will expire no more than ten years from their dates of grant. The exercise price of each option shall be determined by the administrator of the Ignyta Plan, which is the Board of Directors, and shall not be less than 100% of the fair market value of the Company’s common stock on the date the option is granted. Generally, options are granted with an exercise price equal to the fair market value of the Company’s common stock on the date of the option grant. For holders of more than 10% of the Company’s total combined voting power of all classes of stock, incentive stock options may not be granted at less than 110% of the fair market value of the Company’s common stock on the date of grant and for a term not to exceed five years.
		A summary of the Company’s stock option activity and related information is as follows:
		Options			Weighted-		Weighted-		Aggregate
		Outstanding			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term
	Balance at December 31, 2011		12,500		$	0.18		—	$	—
	Granted		144,159			0.39		—		—
	Exercised		—			—		—		—
	Cancelled		—			—		—		—
	Balance at December 31, 2012		156,659			0.36		—		—
	Granted		1,061,325			4.6		—		—
	Exercised		(12,290	)		0.24		—		—
	Expired		(2,154	)		0.54		—		—
	Forfeited		(70,387	)		0.45		—		—
	Balance at December 31, 2013		1,133,153		$	4.33		9.71	$	3,026,430
	Exercisable at December 31, 2013		111,920		$	0.54		8.88	$	722,829
		The fair value of options granted to employees and non-employee directors was estimated at the date of grant using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		2013		2012
	Risk free interest rate	1.92%		0.92%
	Dividend yield	0.00%		0.00%
	Volatility	59.26%		62.01%
	Weighted-average expected life of option (years)	6.1		5.9
		The estimated weighted-average per-share fair value of stock options granted to employees and non-employee directors for the years ended December 31, 2013 and 2012 was $2.83 and $0.18, respectively.
		The fair value of options granted to non-employees was estimated at the vesting date using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		2013		2012
	Risk free interest rate	2.61%		1.77%
	Dividend yield	0.00%		0.00%
	Volatility	58.16%		90.00%
	Weighted-average expected life of option (years)	10		10
		The estimated weighted-average per-share fair value of stock options granted to non-employees for the years ended December 31, 2013 and 2012 was $1.59 and $0.39, respectively.
		Dividend Yield—The Company has never declared or paid dividends on common stock and has no plans to do so.
		Expected Volatility—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated or is expected to fluctuate during a period. The Company considered the historical volatility of peer companies and business and economic considerations in order to estimate the expected volatility, due to the Company not being publicly traded for a significant period.
		Risk-Free Interest Rate—This is the U.S. Treasury rate for the day of each option grant during the quarter having a term that most closely resembles the expected life of the option.
		Expected Life of the Option Term—This is the period of time that the options granted are expected to remain unexercised. Options granted during the period have a maximum contractual term of ten years. The Company estimates the expected life of the option term based on the simplified method as defined in Staff Accounting Bulletin 110. For non-employee options granted, this is the remaining contractual term of the option as of the reporting date.
		Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company assesses the forfeiture rate on an annual basis and revises the rate when deemed necessary.
		Stock-based compensation expense for employees and non-employees for the years ended December 31, 2013 and 2012 and the period from inception (August 29, 2011) through December 31, 2013 was $351,159, $13,333 and $364,613, respectively. For the years ended December 31, 2013 and 2012 and the period from inception (August 29, 2011) through December 31, 2013, $220,888, $6,845 and $227,733 was recorded to research and development, respectively and $130,271, $6,488, and $136,880 was recorded to general and administrative, respectively.
		As of December 31, 2013, there was an additional $3,027,539 of total unrecognized compensation cost related to unvested stock-based awards granted under the Ignyta Plan. This unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.74 years.
	Restricted stock activity	In 2011, Ignyta Operating sold 666,668 shares of restricted common stock for proceeds of $2,000, in accordance with restricted stock purchase agreements with various advisors. Approximately 600,000 shares were vested immediately and the remaining 66,668 are subject to vesting requirements based on future service.
		Terms of each of the agreements state that the Company has the right to repurchase the unvested shares of stock if the shareholder stops providing service. The Company repurchased 13,334 shares of common stock in 2012. The Company recorded stock-based compensation expense, calculated as the difference between the fair value of the common stock at each reporting period less the proceeds received, upon vesting of the restricted stock. Related stock-based compensation for the years ended December 31, 2013 and 2012 and the period from inception (August 29, 2011) through December 31, 2013 was $19,280, $10,040 and $29,980, respectively. All restricted stock was expensed to research and development. At December 31, 2013, 631,334 shares were vested and 22,000 shares remain unvested.
		In May 2013, Ignyta Operating entered into an Agreement and Plan of Reorganization with Actagene. In accordance with the agreement, Actagene was merged into Ignyta Operating, and the separate corporate existence of Actagene ceased, with Ignyta Operating continuing as the surviving corporation. On May 20, 2013, the merger was effected and Ignyta Operating issued 1,583,336 shares of restricted common stock in exchange for the cancellation of all of the outstanding shares of Actagene (see Note 3). Approximately 1,000,000 shares were vested immediately and the remaining 583,336 are subject to vesting requirements based on future service. The shares vest over 3 years, with one-third vesting in February 2014 and the remaining shares vesting over the next 24 months.
		All of the foregoing restricted stock was exchanged for shares of Ignyta, Inc. common stock in connection with the Merger (see Note 2).

Warrants

Warrants	12 Months Ended
	Dec. 31, 2013
Warrants	'
	8. Warrants	On November 6, 2013, Nerviano Medical Sciences S.r.l. (“NMS”) was issued a warrant to acquire up to 16,667 shares of our common stock in connection with the license agreement between the Company and NMS. The warrant has an exercise price of $6.00 per share and is exercisable at the option of the holder, in whole or in part, at any time until November 6, 2018. The terms of such warrant provide for adjustments in the event of certain stock dividends, stock splits, recapitalizations, reclassifications and consolidations. Upon exercise, the aggregate exercise price of the warrant issued is payable by NMS in cash.
		The Company recognized warrant expense of $47,600 using a binomial model with an exercise price of $6.00, risk free interest rate of 1.68%, volatility of 54.8%, and a useful life of 4.85 years. The entire amount was expensed to research and development in 2013.
		During 2012, Ignyta Operating issued a warrant to purchase 8,334 shares of Series B Preferred Stock in connection with the Loan Agreement. The warrant was assumed by Ignyta, Inc. in connection with the Merger (see Note 2). The exercise price of the warrant is $3.00 per share.
		On February 27, 2013, Ignyta Operating issued a warrant to purchase up to a number of shares of Series B Preferred Stock equal to 5% of the amount loaned under the Loan Agreement on February 27, 2013 and thereafter, subject to adjustment as set forth in the warrant, including without limitation for stock combinations and splits. As a result, following the February 2013 and July 2013 advances under the Loan Agreement, the warrant became exercisable for 16,667 shares of Ignyta Operating’s Series B Preferred Stock. The warrant was assumed by Ignyta, Inc. in connection with the Merger. The exercise price of the warrant is $3.00 per share and the warrant expires February 27, 2020.
		The exercise price of the warrants issued in conjunction with the loan financing is protected against dilutive financing through the term of the warrants. Pursuant to ASC 815-15 and ASC 815-40, the fair value of the warrants was recorded as a derivative liability on the issuance dates.
		Each of the warrants was valued at the grant date and at the end of each reporting period thereafter.
		The Company revalued all of the warrants at the end of each reporting period, and the estimated fair value of the outstanding warrant liability was $129,400 and $24,500 at December 31, 2013 and 2012, respectively. The change in the estimated fair value of the derivative liability resulted in other expense of $76,600 and $0 for the periods ended December 31, 2013 and 2012, respectively.
		The derivative liabilities were valued at their issuance dates and at the end of each reporting period using a binomial pricing model and the following weighted average assumptions:
		December 31, 2013	December 31, 2012
	Expected volatility	59.20%	176.40%
	Risk-free interest rate	2.12%	1.18%
	Dividend yield	0.00%	0.00%
	Remaining expected term of underlying securities (years)	6.07	6.5

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
	9. Income Taxes	As of December 31, 2013 and 2012, a non-current deferred tax asset of approximately $6,008,000 and $553,000, respectively, had been recognized for the temporary differences primarily related to federal and state net operating losses and research and development credits.
		A valuation allowance has been recorded to fully offset the deferred tax asset as it is more likely than not that the assets will not be fully utilized. The valuation allowance at December 31, 2013 was approximately $6,008,000 and increased approximately $5,455,000 during 2013.
		At December 31, 2013, the Company had unused federal and state net operating losses of approximately $7,251,000 and $7,115,000, respectively.
		The federal and state tax net operating loss carryforwards will begin to expire in 2031, and California carryforwards have no expiration.
		Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within a three-year period. These financial statements do not contain any adjustment relating to such potential limitations.
		The Company is subject to tax in the United States and in the state of California. As of December 31, 2013, the Company’s tax years from inception are subject to examination by the tax authorities. The Company is not currently under examination by any U.S. federal or state jurisdictions.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
	10. Commitments and Contingencies
	Operating leases	The Company leases office space under non-cancelable operating leases expiring on various dates through August 2016. The Company incurred rent expense under those operating leases of approximately $146,952, $23,988 and $176,872 for the years ended December 31, 2013 and 2012, and for the period from inception (August 29, 2011) through December 31, 2013, respectively
		The Company leases lab equipment under a non-cancelable operating lease that expires in March 2016. Monthly payments are $5,758. The Company incurred rent expense under that operating lease of $60,620, $0 and $60,620 for the years ended December 31, 2013 and 2012, and for the period from inception (August 29, 2011) through December 31, 2013, respectively.
		Future minimum lease payments required under the operating leases are as follows:
	Year Ending December 31,
	2014	$	222,844
	2015		191,555
	2016		106,983
	2017		—
	Total	$	521,382
	License agreements	The Company entered into an agreement with NMS on October 10, 2013, which was amended on October 25, 2013 and became effective on November 6, 2013, whereby the Company obtained an exclusive license in certain of NMS’ Active Pharmaceutical Ingredients (APIs) and certain NMS IP rights upon the effective date of the agreement. An initial payment of $7,000,000 was paid in November 2013. The entire amount was expensed to research and development in 2013 as no future benefit can be determined at this time. In addition, NMS was issued on November 6, 2013 a five year warrant to purchase 16,667 shares of our common stock at an exercise price per share of six dollars ($6.00). Tiered royalties in the low single digits to mid double digits will be paid based upon aggregate annual net sales. The agreement also requires that the Company makes development and regulatory milestone payments to NMS of up to $105.0 million in the aggregate if specified clinical study initiations and regulatory approvals are achieved across multiple products or indications. The first such milestone payment is not due until the Company elects to initiate the first randomized Phase II clinical study, which, based on its current estimates and certain assumptions, the Company anticipates could occur as early as 2015. The Company is obligated under the terms of the license agreement to engage NMS to perform services valued at $1 million or more between the effective date of the license agreement and December 31, 2014, which services could include, among others at the Company’s election, manufacture and supply services, technology transfer activities, preclinical activities, process development activities and assay development activities. As of December 31, 2013, approximately $80,000 of services were performed.
		In March 2012, the Company entered into a license agreement with a university for the use of certain patented rights relating to molecular diagnostics. The Company has delivered notice to the university of the Company’s exercise of its right to terminate the license agreement, effective as of April 2014. Under the agreement, the Company was required to make annual license payments of $15,000. The Company made the first license payment under the agreement in 2012 and its annual license payment under the agreement in 2013. These payments were amortized monthly and expensed to research and development.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2013
Concentrations	'
	11. Concentrations
	Credit risk	The Company maintains cash balances at various financial institutions. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. At times these balances exceed federally insured limits. The Company has not experienced any losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

Related_Parties

Related Parties	12 Months Ended
	Dec. 31, 2013
Related Parties	'
	12. Related Parties	In 2012, the Company executed an employee lease agreement with its majority stockholder. Under the terms of the agreement, the Company is reimbursed for certain administrative services provided to the related party. In addition, the Company was reimbursed for various operating expenses related to shared utilities and telecommunications and/or may make payments to its majority shareholder for these shared operating expenses.
		Total reimbursements received during the years ended December 31, 2013 and 2012 and the period from inception (August 29, 2011) through December 31, 2013 were $5,704, $14,025 and $19,729, respectively. There was $0 and $4,478 in accounts receivable at December 31, 2013 and 2012, respectively. Total payments made during the years ended December 31, 2013 and 2012 and the period from inception (August 29, 2011) through December 31, 2013 were $23,723, $11,750 and $39,050, respectively. There was $312 and $1,811 in accounts payable at December 31, 2013 and 2012, respectively.
		In May 2013, Ignyta Operating and Actagene effected a merger pursuant to which Actagene merged with and into Ignyta Operating. The majority stockholder of Ignyta Operating was also the majority stockholder of Actagene, and representatives of the majority stockholder controlled the day to day operations and were on the board of directors of each entity (see Note 3).

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events	'
	13. Subsequent Events
	Repurchase of Restricted Stock	On February 5, 2014, due to the termination of employment of an employee, the Company repurchased 400,000 shares of restricted stock for $1,440 pursuant to the restricted stock purchase agreement between the Company and such employee.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Nature of operations	'
	Nature of operations		Ignyta, Inc. was founded in 2012 and is incorporated in the state of Nevada. On October 31, 2013, Ignyta Operating, Inc. (a Delaware corporation founded in 2011 and previously named Ignyta, Inc.) merged with and into IGAS Acquisition Corp., a wholly-owned subsidiary of Ignyta, Inc., which was previously named “Infinity Oil & Gas Company” (see Note 2). As used in these financial statements, unless the context indicates or otherwise requires, the “Company”, “we”, “us”, and “our” refer to Ignyta, Inc. and its consolidated subsidiary, and the term “Ignyta Operating” refers to Ignyta Operating, Inc.
			In May 2013, Ignyta Operating acquired Actagene Oncology, Inc. (“Actagene”), a San Diego based privately held biotechnology company developing precision medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. With the acquisition, Ignyta Operating changed its business strategy from a prior focus on molecular diagnostics for autoimmune disease to an integrated drug and diagnostic, or Rx/Dx, focus on drug and biomarker discovery and development for oncology (see Note 3).
			The Company is a precision medicine biotechnology company dedicated to discovering or acquiring, then developing and commercializing precisely targeted new drugs for cancer patients whose tumors harbor specific molecular alterations. The Company pursues an Rx/Dx strategy, where it aims to pair each of its innovative drugs with biomarker-based companion diagnostics, developed by the Company or by third parties with which it may partner, that are designed to identify the patients that are most likely to benefit from the use of the drugs that the Company may develop.
Consolidation	'
	Consolidation		The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). All significant intercompany balances and transactions have been eliminated in consolidation.
Development stage	'
	Development stage		As of December 31, 2013, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure, and has not realized revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.
Liquidity	'
	Liquidity		As of December 31, 2013, the Company had an accumulated deficit of approximately $15,573,000. The Company also had negative cash flow from operations of approximately $13,073,000 during the twelve months ended December 31, 2013.
			On November 6, 2013, the Company completed a Private Investment in Public Equity (“PIPE”) financing where it issued 7,740,142 shares of its common stock to 52 accredited investors at six dollars ($6.00) per share for gross proceeds of approximately $46.4 million (see Note 6).
			On November 29, 2013, the Company completed a Subsequent Private Placement with 195 accredited investors providing for the issuance and sale to such investors of an aggregate of 1,270,096 shares of its common stock at a purchase price of six dollars ($6.00) per share for gross proceeds of approximately $7.6 million (see Note 6).
			On December 31, 2013, the Company entered into an amended and restated loan and security agreement with a financial institution with gross proceeds totaling approximately $10,000,000 (see Note 5).
			The Company will need additional capital to further fund development, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are currently focused primarily on the development of our RXDX-101, RXDX-102, Spark-1, Spark-2 and Spark-3 programs, which we believe will result in our continued incurrence of significant research and development and other expenses related to those programs. If the clinical trials for any of our products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to
			achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing from existing and prospective investors. We cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.
			While we expect that our existing cash and cash equivalents will enable us to fund our operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require us to delay, reduce, or eliminate some or all of our development programs. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
Use of estimates	'
	Use of estimates		The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in computing the valuation allowance on deferred tax assets, the valuation of warrants, and those assumed in calculating stock-based compensation expense.
Cash and cash equivalents	'
	Cash and cash equivalents		The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash equivalents primarily represent amounts invested in money market funds whose cost equals market value.
Fixed assets	'
	Fixed assets		Fixed assets are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally three to five years, or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the lease term.
Impairment of long-lived assets	'
	Impairment of long-lived assets		In accordance with authoritative guidance related to impairment or disposal of long-lived assets, management reviews the Company’s long-lived asset groups for impairment whenever events indicate that their carrying amount may not be recoverable. When management determines that one or more impairment indicators are present for an asset group, it compares the carrying amount of the asset group to net future undiscounted cash flows that the asset group is expected to generate. If the carrying amount of the asset group is greater than the net future undiscounted cash flows that the asset group is expected to generate, it compares the fair value to the book value of the asset group. If the fair value is less than the book value, it recognizes an impairment loss. The impairment loss would be the excess of the carrying amount of the asset group over its fair value. To date, the Company has not experienced any impairment losses on its long-lived assets used in operations.
Stock-based compensation	'
	Stock-based compensation		The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation—Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
			The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
Fair value of financial instruments	'
	Fair value of financial instruments		The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses, and notes payable. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of December 31, 2013 and December 31, 2012, the carrying amounts are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
Derivative liabilities	'
	Derivative liabilities		The Company accounts for its warrants as either equity or liabilities based upon the characteristics and provisions of each instrument. Warrants classified as derivative liabilities are recorded on the Company’s balance sheet at their fair value on the date of issuance and revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future events, expected volatility, expected life, yield, and risk free interest rate.
Income taxes	'
	Income taxes		Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
Earnings Per Share ("EPS")	'
	Earnings per share		Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of common shares outstanding. The Company’s basic and fully diluted EPS calculation are the same since the increased number of shares that would be included in the diluted calculation from assumed exercise of stock equivalents would be anti-dilutive to the net loss in each of the years shown in the consolidated financial statements.
	(“EPS”)
Comprehensive income (loss)	'
	Comprehensive income (loss)		Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended December 31, 2013 and 2012, and for the period August 29, 2011 (inception) through December 31, 2013, the comprehensive loss was equal to the net loss.
Research and development costs	'
	Research and development costs		The Company is actively engaged in new product development efforts for which related costs are expensed as incurred.
Fair value measurement	'
	Fair value measurement		Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The following is a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
			•       Level 1—Quoted prices in active markets for identical assets or liabilities.
			•       Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
			•       Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
			As of December 31, 2013, the Company’s Level 1 investments of cash and cash equivalents were comprised of cash in checking accounts.
			The Company used Level 3 inputs for its valuation methodology for the warrant derivative liabilities. The estimated fair values were determined using a binomial option pricing model based on various assumptions (see Note 8). The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to fair value of derivative liabilities.
			At December 31, 2013, the estimated fair values of the liabilities measured on a recurring basis are as follows:
	Fair Value Measurements at December 31, 2013
	Balance at				Quoted Prices in	Significant	Significant
					Active Markets	Other	Other
	December 31, 2013				(Level 1)	Observable	Unobservable
						Inputs (Level 2)	Inputs (Level 3)
	$	129,400			—	—	$	129,400
	Fair Value Measurements at December 31, 2012
	Balance at				Quoted Prices in	Significant	Significant Other
							Unobservable
	December 31, 2012				Active Markets	Other	Inputs (Level 3)
					(Level 1)	Observable
						Inputs (Level 2)
	$	24,500			—	—	$	24,500
			The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the twelve months ended December 31, 2013:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
			Warrant Derivative
			Liability
	Beginning Balance at December 31, 2011		$	—
	Issuances			24,500
	Ending Balance at December 31, 2012		$	24,500
	Issuances			28,300
	Adjustments to estimated fair value			76,600
	Ending Balance at December 31, 2013		$	129,400

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Estimated fair values of the liabilities measured on a recurring basis	'
	At December 31, 2013, the estimated fair values of the liabilities measured on a recurring basis are as follows:
	Fair Value Measurements at December 31, 2013
	Balance at				Quoted Prices in	Significant	Significant
					Active Markets	Other	Other
	December 31, 2013				(Level 1)	Observable	Unobservable
						Inputs (Level 2)	Inputs (Level 3)
	$	129,400			—	—	$	129,400
	Fair Value Measurements at December 31, 2012
	Balance at				Quoted Prices in	Significant	Significant Other
							Unobservable
	December 31, 2012				Active Markets	Other	Inputs (Level 3)
					(Level 1)	Observable
						Inputs (Level 2)
	$	24,500			—	—	$	24,500
			The following table presents the activity for liabilities measured at estimated fair value using unobservable inputs for the twelve months ended December 31, 2013:
	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
			Warrant Derivative
			Liability
	Beginning Balance at December 31, 2011		$	—
	Issuances			24,500
	Ending Balance at December 31, 2012		$	24,500
	Issuances			28,300
	Adjustments to estimated fair value			76,600
	Ending Balance at December 31, 2013		$	129,400

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Fixed Assets	'
		Fixed assets consisted of the following:
			December 31,
			2013			2012
	Manufacturing and lab equipment		$	775,872		$	288,434
	Office furniture and equipment			59,095			6,646
	Computers			110,857			7,332
	Leasehold improvements			—			5,957
				945,824			308,369
	Less accumulated depreciation and amortization			(115,118	)		(13,892	)
			$	830,706		$	294,477

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2013
Future Minimum Principal Payments on Notes Payable	'
	Future minimum principal payments on notes payable are as follows:
	Year ending December 31,
	2014	$	—
	2015		3,103,479
	2016		3,327,074
	2017		3,569,447
	Total	$	10,000,000

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Stock Option Activity	'
		A summary of the Company’s stock option activity and related information is as follows:
		Options			Weighted-		Weighted-		Aggregate
		Outstanding			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term
	Balance at December 31, 2011		12,500		$	0.18		—	$	—
	Granted		144,159			0.39		—		—
	Exercised		—			—		—		—
	Cancelled		—			—		—		—
	Balance at December 31, 2012		156,659			0.36		—		—
	Granted		1,061,325			4.6		—		—
	Exercised		(12,290	)		0.24		—		—
	Expired		(2,154	)		0.54		—		—
	Forfeited		(70,387	)		0.45		—		—
	Balance at December 31, 2013		1,133,153		$	4.33		9.71	$	3,026,430
	Exercisable at December 31, 2013		111,920		$	0.54		8.88	$	722,829
Assumptions Used to Estimate Fair Value of Options Granted	'
		The fair value of options granted to employees and non-employee directors was estimated at the date of grant using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		2013		2012
	Risk free interest rate	1.92%		0.92%
	Dividend yield	0.00%		0.00%
	Volatility	59.26%		62.01%
	Weighted-average expected life of option (years)	6.1		5.9
		The estimated weighted-average per-share fair value of stock options granted to employees and non-employee directors for the years ended December 31, 2013 and 2012 was $2.83 and $0.18, respectively.
		The fair value of options granted to non-employees was estimated at the vesting date using a Black-Scholes option pricing model with the weighted-average assumptions stated below.
		2013		2012
	Risk free interest rate	2.61%		1.77%
	Dividend yield	0.00%		0.00%
	Volatility	58.16%		90.00%
	Weighted-average expected life of option (years)	10		10

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Valuation of Derivative Liabilities Using a Binomial Pricing Model with Weighted Average Assumptions	'
	The derivative liabilities were valued at their issuance dates and at the end of each reporting period using a binomial pricing model and the following weighted average assumptions:
		December 31, 2013	December 31, 2012
	Expected volatility	59.20%	176.40%
	Risk-free interest rate	2.12%	1.18%
	Dividend yield	0.00%	0.00%
	Remaining expected term of underlying securities (years)	6.07	6.5

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Future Minimum Lease Payments Under the Operating Leases	'
	Future minimum lease payments required under the operating leases are as follows:
	Year Ending December 31,
	2014	$	222,844
	2015		191,555
	2016		106,983
	2017		—
	Total	$	521,382

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended		28 Months Ended		1 Months Ended				12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Feb. 27, 2013	Nov. 29, 2013	Nov. 06, 2013	Nov. 29, 2013	Nov. 06, 2013	Dec. 31, 2013	Dec. 31, 2013
					Private Investment in Public Equity ( the "PIPE" Financing")	Private Investment in Public Equity ( the "PIPE" Financing")	Private Investment in Public Equity ( the "PIPE" Financing")	Private Investment in Public Equity ( the "PIPE" Financing")	Minimum	Maximum
					Investor	Investor	Common Stock	Common Stock
Accounting Policies [Line Items]	'	'	'	'	'	'	'	'	'	'
Retained Earnings (Accumulated Deficit)	$15,572,940	$1,359,297	$15,572,940	'	'	'	'	'	'	'
Net cash used in operating activities	-13,073,072	-990,611	-14,128,307	'	'	'	'	'	'	'
Stock issued	'	'	'	'	'	'	1,270,096	7,740,142	'	'
Sales of Stock, price per share	'	'	'	'	'	'	$6	$6	'	'
Gross proceeds from sale of stock	'	'	'	'	'	'	7,600,000	46,400,000	'	'
Number of Accredited Investors	'	'	'	'	195	52	'	'	'	'
Loan, maximum borrowing amount	$10,000,000	$500,000	$10,000,000	$1,500,000	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'	'	'	'	'	'	'3 years	'5 years

Significant_Accounting_Policie

Significant Accounting Policies - Fair Value of Liabilities Measured on Recurring Basis (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair values of the liabilities measured on a recurring basis	$129,400	$24,500
Significant Other Unobservable Inputs (Level 3)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair values of the liabilities measured on a recurring basis	$129,400	$24,500

Significant_Accounting_Policie1

Significant Accounting Policies - Fair Value Measurements Using Significant Unobservable Inputs (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance	$24,500	'
Issuances	28,300	24,500
Adjustments to estimated fair value	76,600	'
Ending Balance	$129,400	$24,500

Reverse_Merger_Additional_Info

Reverse Merger - Additional Information (Detail)	1 Months Ended
	Oct. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]	'	'	'	'
Conversion basis of preferred stock to common stock	'One-to-one	'	'	'
Reverse stock split ratio	0.01	'	'	'
Common Stock, shares outstanding	'	13,934,876	653,334	'
Share based compensations, Outstanding option	'	1,133,153	156,659	12,500
Series A Convertible Preferred Stock	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Reverse stock split ratio	0.3333	'	'	'
Merger Transactions	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Conversion basis of preferred stock to common stock	'One-to-one	'	'	'
Common Stock, shares outstanding	4,916,469	'	'	'
Ownership percentage by former stock holders of Ignyta	99.85%	'	'	'
Shares reserved for issuance pursuant to future equity grants	342,209	'	'	'
Merger Transactions | 2011 Equity Incentive Plan	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Share based compensations, Outstanding option	358,986	'	'	'
Merger Transactions | Series A Convertible Preferred Stock	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Reverse stock split ratio	0.3333	'	'	'
Merger Transactions | Common Stock	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Warrants to purchase stock, outstanding	25,001	'	'	'

Actagene_Merger_Additional_Inf

Actagene Merger - Additional Information (Detail) (Actagene Merger)	0 Months Ended
	20-May-13
Actagene Merger	'
Business Acquisition [Line Items]	'
Common Stock in exchange for the cancellation of all of the outstanding shares of Actagene	1,583,336
Percentage of voting power in each entity	60.00%

Components_of_Fixed_Assets_Det

Components of Fixed Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Manufacturing and lab equipment	$775,872	$288,434
Office furniture and equipment	59,095	6,646
Computers	110,857	7,332
Leasehold improvements	'	5,957
Property, Plant and Equipment, Gross, Total	945,824	308,369
Less accumulated depreciation and amortization	-115,118	-13,892
Fixed Assets-Net	$830,706	$294,477

Fixed_Assets_Additional_Disclo

Fixed Assets - Additional Disclosure (Detail) (USD $)	12 Months Ended		28 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation Expense	$112,380	$13,892	$126,272

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended	12 Months Ended		28 Months Ended
	Feb. 27, 2013	Jun. 28, 2012	Jul. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jul. 31, 2013	Feb. 27, 2013	Dec. 31, 2012	Jun. 30, 2012
							Series B Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B Convertible Preferred Stock
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Loan, maximum borrowing amount	$1,500,000	'	'	$10,000,000	$500,000	$10,000,000	'	'	'	'
Final payment of borrowing, presented as debt discount	'	'	'	1,050,000	'	1,050,000	'	'	'	'
Interest on final payment	'	'	'	10.50%	'	'	'	'	'	'
Principal and interest payment period commencing after period of interest only payments	'30 months	'36 months	'24 months	'36 months	'	'	'	'	'	'
Interest only payments period	'6 months	'15 months	'2 months	'12 months	'	'	'	'	'	'
Fixed interest on the advanced amount	4.00%	4.77%	4.04%	6.92%	'	6.92%	'	'	'	'
Loan amount advanced	500,000	500,000	500,000	11,000,000	500,000	11,500,000	'	'	'	'
Warrant to purchase stock, shares	'	'	'	'	'	'	16,667	16,667	8,334	8,334
Percentage of loan agreement up to a number of stock on which warrant to purchase common stock issued	'	'	'	'	'	'	'	5.00%	'	'
Warrants issued with debt financing recorded as debt discount	'	'	'	28,300	24,500	52,800	'	'	'	'
Interest expense due to amortization of the debt discount	'	'	'	$48,470	$4,330	$52,800	'	'	'	'

Note_Payable_Future_Minimum_Pr

Note Payable - Future Minimum Principal Payments on Notes Payable (Detail) (USD $)	Dec. 31, 2013
Debt Instrument [Line Items]	'
2014	'
2015	3,103,479
2016	3,327,074
2017	3,569,447
Total	$10,000,000

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

28 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Oct. 30, 2013

Oct. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Oct. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Nov. 29, 2013

Nov. 06, 2013

Nov. 29, 2013

Nov. 06, 2013

Series A Convertible Preferred Stock

Series A Convertible Preferred Stock

Series A Convertible Preferred Stock

Series A Convertible Preferred Stock

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Series B Convertible Preferred Stock

Private Investment in Public Equity ( the "PIPE" Financing")

Private Investment in Public Equity ( the "PIPE" Financing")

Private Investment in Public Equity ( the "PIPE" Financing")

Private Investment in Public Equity ( the "PIPE" Financing")

Investor

Investor

Common Stock

Common Stock

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, shares authorized

'

100,000,000

100,000,000

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, shares authorized

'

10,000,000

0

10,000,000

'

'

2,500,000

'

0

'

7,000,000

0

'

'

'

'

Common stock, voting right description

'

'Common stock is entitled to one vote and all shares rank equally as to voting and other matters.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of Preferred Stock net of offering costs

'

'

'

'

'

'

416,667

416,667

'

'

1,835,000

'

'

'

1,270,096

7,740,142

Issuance of Preferred Stock, price per share

'

'

'

'

'

'

$0.60

$0.60

'

'

$3

'

'

'

$6

$6

Gross proceeds from sale of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,600,000

$46,400,000

Number of Accredited Investors

'

'

'

'

'

'

'

'

'

'

'

'

195

52

'

'

Reverse stock split ratio

0.01

'

'

'

'

0.3333

'

'

'

0.3333

'

'

'

'

'

'

Common Stock, par value

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of preferred stock

'

'

$5,673,173

$5,893,951

'

'

$250,000

$250,000

'

'

$5,505,000

'

'

'

'

'

Conversion basis of preferred stock to common stock

'One-to-one

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)

12 Months Ended

28 Months Ended

0 Months Ended

12 Months Ended

28 Months Ended

12 Months Ended

28 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Oct. 31, 2013

Feb. 28, 2013

20-May-13

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Actagene Merger

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Employee Stock Option

Employee Stock Option

Non-Employee Stock Options

Non-Employee Stock Options

Restricted Stock

Restricted Stock

Research and Development Expense [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Maximum

Minimum

For holders of more than 10% of the Company's total combined voting power of all classes of stock

For holders of more than 10% of the Company's total combined voting power of all classes of stock

Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock available for issuance

2,712,652

'

166,666

2,712,652

712,652

666,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock reserved for issuance

'

'

'

'

'

'

'

2,712,652

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares that remained available for grant

'

'

'

'

'

'

'

1,567,209

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options expiration period from their date of grant

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of option as a percentage of fair market value of Common Stock on the grant date

'

'

'

'

'

'

'

'

'

100.00%

'

110.00%

'

'

'

'

'

'

'

'

'

'

'

'

Stock options granted, term

'

'

'

'

'

'

'

'

'

'

'Five years

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated weighted-average fair value of stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

$2.83

$0.18

$1.59

$0.39

'

'

'

'

'

'

'

'

Options granted during period, maximum contractual term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'

'

'

'

'

'

'

Stock-based compensation expense for employees and non-employees

$351,159

$13,333

'

$364,613

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$220,888

$6,845

$227,733

$130,271

$6,488

$136,880

Unrecognized compensation cost related to unvested stock-based awards

3,027,539

'

'

3,027,539

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested stock-based awards, weighted average period of recognition

'

'

'

'

'

'

'

'1 year 8 months 27 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock in exchange for the cancellation of all of the outstanding shares of Actagene

'

'

666,668

'

'

'

1,583,336

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceed from sale of shares of restricted stock

51,013,741

'

2,000

51,013,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of restricted stock, vested

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

631,334

600,000

'

'

'

'

'

'

Shares of restricted stock, unvested

'

'

'

'

'

'

583,336

'

'

'

'

'

'

'

'

'

22,000

66,668

'

'

'

'

'

'

Shares of Common stock repurchased

'

13,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation, restricted stock

$19,280

$10,040

'

$29,980

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Option Activity and Related Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Options Outstanding	'	'
Balance at beginning of period	156,659	12,500
Granted	1,061,325	144,159
Exercised	-12,290	'
Cancelled	'	'
Expired	-2,154	'
Forfeited	-70,387	'
Balance at end of period	1,133,153	156,659
Exercisable at end of period	111,920	'
Weighted -Average Exercise Price	'	'
Balance at beginning of period	$0.36	$0.18
Granted	$4.60	$0.39
Exercised	$0.24	'
Cancelled	'	'
Expired	$0.54	'
Forfeited	$0.45	'
Balance at end of period	$4.33	$0.36
Exercisable at end of period	$0.54	'
Weighted- Average Remaining Contractual Term	'	'
Balance at end of period	'9 years 8 months 16 days	'
Exercisable at end of period	'8 years 10 months 17 days	'
Aggregate Intrinsic Value	'	'
Balance at end of period	$3,026,430	'
Exercisable at end of period	$722,829	'

StockBased_Compensation_Assump

Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Options Granted to Employees and Non-employee Directors (Detail) (Employee and Non-employee Directors Stock Options)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee and Non-employee Directors Stock Options	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk free interest rate	1.92%	0.92%
Dividend yield	0.00%	0.00%
Volatility	59.26%	62.01%
Weighted-average expected life of option (years)	'6 years 1 month 6 days	'5 years 10 months 24 days

StockBased_Compensation_Assump1

Stock-Based Compensation - Assumptions Used to Estimate Fair Value of Options Granted to Non-employees (Detail) (Non-Employee Stock Options)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Non-Employee Stock Options	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk free interest rate	2.61%	1.77%
Dividend yield	0.00%	0.00%
Volatility	58.16%	90.00%
Weighted-average expected life of option (years)	'10 years	'10 years

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)	12 Months Ended		28 Months Ended	1 Months Ended				1 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Feb. 27, 2013	Jul. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Nov. 06, 2013	Dec. 31, 2013
				Series B Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B Convertible Preferred Stock	Series B Convertible Preferred Stock	Licensing Agreements, Nerviano Medical agreement Sciences S.r.l. (NMS)	Licensing Agreements, Nerviano Medical agreement Sciences S.r.l. (NMS)
								Common Stock	Common Stock
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Warrant to purchase stock, shares	'	'	'	16,667	16,667	8,334	8,334	16,667	'
Warrant exercise price per share	'	'	'	3	'	3	'	6	'
Warrant exercise period	'	'	'	'	'	'	'	6-Nov-18	'
Warrant expense	$47,600	'	$47,600	'	'	'	'	'	$47,600
Exercise price	'	'	'	'	'	'	'	'	$6
Risk-free interest rate	2.12%	1.18%	'	'	'	'	'	'	1.68%
Expected volatility	59.20%	176.40%	'	'	'	'	'	'	54.80%
Useful life	'6 years 26 days	'6 years 6 months	'	'	'	'	'	'	'4 years 10 months 6 days
Percentage of loan agreement up to a number of stock on which warrant to purchase common stock issued	'	'	'	5.00%	'	'	'	'	'
Warrant expiry date	'	'	'	27-Feb-20	'	'	'	'	'
Estimated fair value of outstanding warrant liability	129,400	24,500	129,400	'	'	'	'	'	'
Change in the estimated fair value of the derivative liability	($76,600)	$0	($76,600)	'	'	'	'	'	'

Valuation_of_Derivative_Liabil

Valuation of Derivative Liabilities Using a Binomial Pricing Model with Weighted Average Assumptions (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Expected volatility	59.20%	176.40%
Risk-free interest rate	2.12%	1.18%
Dividend yield	0.00%	0.00%
Remaining expected term of underlying securities (years)	'6 years 26 days	'6 years 6 months

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax [Line Items]	'	'
Non-current deferred tax asset	$6,008,000	$553,000
Valuation allowance	6,008,000	'
Valuation allowance increase during period	5,455,000	'
Federal and state tax net operating loss carryforwards, beginning period of expiration	'2031	'
Federal [Member]	'	'
Income Tax [Line Items]	'	'
Net operating losses	7,251,000	'
State and Local Jurisdiction	'	'
Income Tax [Line Items]	'	'
Net operating losses	$7,115,000	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

28 Months Ended

12 Months Ended

28 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Nov. 06, 2013

Dec. 31, 2013

Nov. 06, 2013

Nov. 06, 2013

Nov. 06, 2013

First Office Building

First Office Building

First Office Building

Equipment [Member]

Equipment [Member]

Equipment [Member]

Licensing Agreements, Nerviano Medical agreement Sciences S.r.l. (NMS)

Licensing Agreements, Nerviano Medical agreement Sciences S.r.l. (NMS)

Licensing Agreements, Nerviano Medical agreement Sciences S.r.l. (NMS)

Licensing Agreements, Nerviano Medical agreement Sciences S.r.l. (NMS)

Licensing Agreements, Nerviano Medical agreement Sciences S.r.l. (NMS)

Maximum

Minimum

Common Stock

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Operating leases , rent expense

'

$146,952

$23,988

$176,872

$60,620

$0

$60,620

'

'

'

'

'

Operating leases , expiration dates

'

'Operating leases leases expiring on various dates through August 2016

'

'

'Operating lease that expires in March 2016

'

'

'

'

'

'

'

Operating leases, Monthly rental payment

'

'

'

'

5,758

'

'

'

'

'

'

'

Annual license payments

15,000

'

'

'

'

'

'

7,000,000

'

'

'

'

Warrant to purchase stock, term

'

'

'

'

'

'

'

'

'

'

'

'5 years

Warrant to purchase stock, shares

'

'

'

'

'

'

'

'

'

'

'

16,667

Warrant to purchase stock, exercise price per share

'

'

'

'

'

'

'

'

'

'

'

6

Contingent Milestone payments

'

'

'

'

'

'

'

'

'

105,000,000

'

'

Amount of service to be performed by NMs under the agreement

'

'

'

'

'

'

'

'

'

'

1,000,000

'

Amount of service performed by NMs under the agreement

'

'

'

'

'

'

'

'

$80,000

'

'

'

Operating_Leases_Future_Minimu

Operating Leases Future Minimum Rent Payable (Detail) (USD $)	Dec. 31, 2013
Operating Leased Assets [Line Items]	'
2014	$222,844
2015	191,555
2016	106,983
2017	'
Total	$521,382

Related_Parties_Additional_Inf

Related Parties - Additional Information (Detail) (Majority Stockholder, USD $)	12 Months Ended		28 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Majority Stockholder	'	'	'
Related Party Transaction [Line Items]	'	'	'
Total reimbursements received	$5,704	$14,025	$19,729
Accounts receivable	0	4,478	0
Total payments	23,723	11,750	39,050
Accounts payable	$312	$1,811	$312

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Event, Restricted Stock, USD $)	0 Months Ended
	Feb. 05, 2014
Subsequent Event | Restricted Stock	'
Subsequent Event [Line Items]	'
Stock repurchased during period, shares	400,000
Stock repurchased during period, value	$1,440